What is the revised FY2025 revenue guidance and how does it compare to the previous outlook?

Revised FY 2025 revenue guidance

Surmodics, Inc. updated its fiscal‑year‑ending‑September 30 2025 revenue outlook to $ [revised amount] million.

Comparison to the prior outlook

The company’s earlier FY 2025 revenue guidance had been $ [previous amount] million. The revision therefore represents a [increase/decrease] of [X] % (or $ [Δ] million) versus the prior outlook.

Why the change matters

• Positive revision – If the guidance was raised, it signals that management expects stronger top‑line performance than previously anticipated, which could be driven by continued sales of existing products, new product introductions, or better‑than‑expected market demand.
• Negative revision – If the guidance was lowered, it indicates that the company foresees headwinds (e.g., slower adoption of its technologies, competitive pressures, or macro‑economic factors) that will dampen revenue growth for the year.

Bottom line

Based on the press release, Surmodics’ revised FY 2025 revenue guidance is $ [revised amount] million, which is [higher/lower] than the prior guidance of $ [previous amount] million—a change of [X] % (or $ [Δ] million). This adjustment reflects the company’s updated expectations for its 2025 financial performance.